LDS/Medical Tests/Calprotectin, Fecal

Calprotectin, Fecal

Calprotectin, a major pro-inflammatory cytosolic protein found predominantly in neutrophils with antimicrobial and antiproliferative activities. When inflammatory processes occur, calprotectin is released due to the degranulation of neutrophil granulocytes. It is involved in the tissue damage in IBD, which occurs as a consequence of neutrophil activation and the production of pro-inflammatory mediators. Fecal calprotectin is a marker of infiltration of neutrophils into the mucosa and is a sensitive indicator of intestinal inflammation. Thus, in bowel inflammation, calprotectin is typically found in the stool. An increased calprotectin concentration in stool is the direct consequence of neutrophil degranulation due to mucosal damage. Calprotectin levels are higher in feces than in plasma and significantly elevated in IBD patients (ulcerative colitis and Crohn disease) and in indeterminate colitis.

Calprotectin is the most common marker for suspected IBD and especially for differential diagnosis from other bowel inflammatory diseases such as infection and irritable bowel syndrome. In many cases, patients with IBD may be diagnosed with Crohn’s disease or ulcerative colitis as both disorders are manifested with significant intestinal inflammation. Although this marker has a specificity of >85% for IBD, fecal calprotectin is not a diagnostic marker for IBD, since other inflammatory diseases such as celiac disease, colorectal cancer, and gastrointestinal infections may also express this marker because these diseases are associated with neutrophilic inflammation.

  • Aid in diagnosis of inflammatory bowel disease, including Crohn’s disease and ulcerative colitis
  • Differentiate inflammatory bowel disease from irritable bowel syndrome
  • Therapy monitoring and disease management

Increased in:

  • Active stages of Irritable Bowel Syndrome
  • Irritable Bowel Syndrome
  • Crohn’s disease
  • Ulcerative colitis
  • Other bowel and gastric inflammatory diseases

Decreased in:

  • Response to anti-inflammatory treatment in IBD
  • Normal: <50.0 mcg/g
  • Borderline: 50.1-120.0 mcg/g
  • Abnormal >120.0 mcg/g
Quantitative Enzyme-Linked Immunosorbent Assay (ELISA).

Stool in unpreserved vial; to be refrigerated until evaluation.

Stability

  • Ambient: 5 days
  • Refrigerated: 11 days
  • Frozen: 1 year
Fecal lactoferrin (marker of neutrophil degranulation), C-Reactive Protein (CRP), Electrolyte Panel, Serum, Biopsy, Colon, Stool Culture, Clostridium difficile (C. Diff) by Molecular Method, Ova and Parasites.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Swiss Med Wkly. 2012 Apr 5;142:w13557. [PMID: 22481443]
  • Dig Liver Dis. 2009 Jan;41(1):56-66. [PMID: 18602356]
  • Dig Liver Dis. 2009 Jan;41(1):56-66. [PMID: 18602356]
  • World J Gastroenterol. 2014 Jan 14;20(2):363-75. [PMID: 24574706]
  • BMJ. 2010 Jul 15;341:c3369. [PMID: 20634346]
  • CA Burtis, ER Ashwood, DE Bruns. Tietz textbook of Clinical Chemistry and molecular diagnostics, 5th Ed. Saunders, Philadelphia, New York; 2012.